Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Molecular basis of IFN-α2b use and past indications
- Best use of IFN-α2b as therapy
- Mode of administration
- IFN-α2b use in combination therapy
- Next steps in the study
Biography
Dr. Fish received her B.Sc. from the University of Manchester, UK, her M.Phil. from King’s College, University of London, UK, and her Ph.D. from the Institute of Medical Science at the University of Toronto, Canada. Dr. Fish studies the interactions of cytokines, specifically interferons and chemokines, with their receptors in normal and diseased tissues and cells. A focus of Dr. Fish’s research is the investigation of host-pathogen interactions at the cellular and molecular level, specifically in the context of viruses and interferons. During the 2003 outbreak of SARS in Toronto, she initiated studies to investigate the therapeutic potential of interferon therapy in SARS patients. Encouraging results have directed her group’s efforts toward examining type I interferons’ activities against a number of emerging infectious diseases, such as avian H5N1 and pandemic H1N1 influenza viruses.
During the Ebola virus outbreak in West Africa in 2013-2016, her studies focused on investigating the therapeutic effectiveness of interferon treatment for Ebola virus disease, with a clinical trial in Guinea, with positive outcomes. Dr. Fish was a member of a WHO Working Group to evaluate the therapeutic effectiveness of different antiviral interventions against Ebola virus. Most recently, in an exploratory clinical study in Wuhan, China, she evaluated the therapeutic effectiveness of IFN-α treatment for COVID-19.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Fish, E.N. (2020, October 23). Interferon-α2b as a therapy for COVID-19 [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 5, 2024, from https://doi.org/10.69645/BVCM2953.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Eleanor N. Fish has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)